Stay updated with breaking news from Drug Response. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Boston (May 2, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the early discontinuation of its Phase
Allarity Therapeutics halts Phase 2 trial, citing compelling early results and plans for regulatory advancement. CEO Thomas Jensen affirms strategic shift. ALLR shares surge 38%.
Allarity Therapeutics Inc ALLR shares are trading higher on a strong session volume of 67 million, as per the data from Benzinga Pro. The company announced…
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 -- HUTCHMED Limited today announces that new and updated data from several studies of compounds discovered by HUTCHMED will...
More accurate prognoses and treatments tailored to patients—entrepreneurs claim AI can be harnessed for breakthroughs in beating cancer. One founder is using lab-grown human organs in combination with AI to test drug efficacy.